RA Cap­i­tal jumps on board di­a­betes biotech, pitch­ing in on $160M Se­ries D

A small Cal­i­for­nia biotech is back with more cash and a new big name VC to work with.

Car­mot Ther­a­peu­tics re­port­ed a Se­ries D fi­nanc­ing worth $160 mil­lion Tues­day morn­ing, which the biotech said will be used to push for­ward and com­plete clin­i­cal stud­ies and ad­vance pre-clin­i­cal pro­grams.

Ex­ist­ing backer Col­umn Group led the fi­nanc­ing and was joined by a “sig­nif­i­cant in­vest­ment” from new in­vestor RA Cap­i­tal Man­age­ment, who will hold a board ob­serv­er seat at the com­pa­ny. Ad­di­tion­al fun­ders in­clude Deep Track Cap­i­tal, Wil­lett Ad­vi­sors, Hori­zons Ven­tures and “oth­er in­sti­tu­tion­al in­vestors.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER